Drug intelligence / Profile preview

remifentanil + magnesium sulfate

Development stage: Approved
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of remifentanil, a potent ultra short-acting synthetic opioid μ-receptor agonist, and magnesium sulfate, an NMDA receptor antagonist. This combination is used during general anesthesia to provide analgesia and controlled hypotension. Magnesium sulfate has been shown to reduce remifentanil consumption, improve postoperative analgesia, and decrease the incidence of postoperative nausea and vomiting compared to remifentanil alone.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on remifentanil + magnesium sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on remifentanil + magnesium sulfate.

Explore the full profile